arfolitixorin + fluorouracil + irinotecan

**Arfolitixorin + fluorouracil + irinotecan** is a triple drug combination used as an experimental chemotherapy regimen aimed at treating metastatic colorectal cancer (mCRC). Arfolitixorin is an immediately active form of folate ([6R]-5,10-methylenetetrahydrofolate) designed to enhance the antitumor effect of fluorouracil, a classic cytostatic that inhibits thymidylate synthase and interferes in DNA synthesis. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding, impeding cancer cell replication. This combination seeks to increase efficacy compared to standard regimens using leucovorin by enabling more reliable folate supplementation independent of patient-specific metabolic activation. It is primarily under investigation as part of the ARFIRI regimen for patients with metastatic colorectal cancer, particularly for those unresponsive or less responsive to standard folate-leucovorin regimens[1][2][3][4][7].

Other names

ARFIRI